CNS Pharmaceuticals (NASDAQ:CNSP) Shares Climb 1.5% – What’s Next?

CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) rose 1.5% during mid-day trading on Friday. The company traded as high as $5.40 and last traded at $5.32. 10,901 shares traded hands during trading, an increase of 190% from the average session volume of 3,759 shares. The stock had previously closed at $5.24.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of CNS Pharmaceuticals in a report on Friday, July 17th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company presently has a consensus rating of “Sell”.

CNS Pharmaceuticals Stock Up 1.5%

The firm has a 50-day moving average price of $5.47 and a 200 day moving average price of $4.60. The firm has a market capitalization of $7.77 million, a PE ratio of -0.23 and a beta of 3.10.

CNS Pharmaceuticals (NASDAQ:CNSP) last issued its quarterly earnings data on Wednesday, August 12th. The company reported ($0.38) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.14).

Hedge Funds Weigh In On CNS Pharmaceuticals

A hedge fund recently bought a new position in CNS Pharmaceuticals stock. ADAR1 Capital Management LLC acquired a new stake in CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 70,000 shares of the company’s stock, valued at approximately $335,000. ADAR1 Capital Management LLC owned 4.79% of CNS Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 14.02% of the company’s stock.

About CNS Pharmaceuticals

CNS Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing novel treatments for primary and metastatic cancers of the central nervous system. The company’s research is centered on therapies intended to address the significant challenges associated with treating tumors in the brain and spinal cord, including the blood-brain barrier.

CNS Pharmaceuticals’ lead product candidate is berubicin, an investigational anthracycline designed to cross the blood-brain barrier and reach brain tumors.